FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Slideshows|May 20, 2020
The Neurologic Impact of COVID-19: Early Signs, Past Experience
Author(s)Veronica Hackethal, MD
As neurologic findings among patients with COVID-19 emerge, comparison to sequelae seen with other coronaviruses is instructive.
Advertisement
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.
FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
3
Sentinel Antibodies May Identify Patients With Blunted Vaccine Responses
4
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
5